Share This Page
DEXTROSE 10% IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dextrose 10% In Plastic Container, and when can generic versions of Dextrose 10% In Plastic Container launch?
Dextrose 10% In Plastic Container is a drug marketed by B Braun, Baxter Hlthcare, Fresenius Kabi Usa, Miles, and Otsuka Icu Medcl. and is included in eleven NDAs.
The generic ingredient in DEXTROSE 10% IN PLASTIC CONTAINER is dextrose. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dextrose profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DEXTROSE 10% IN PLASTIC CONTAINER?
- What are the global sales for DEXTROSE 10% IN PLASTIC CONTAINER?
- What is Average Wholesale Price for DEXTROSE 10% IN PLASTIC CONTAINER?
Summary for DEXTROSE 10% IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 5 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| DailyMed Link: | DEXTROSE 10% IN PLASTIC CONTAINER at DailyMed |
US Patents and Regulatory Information for DEXTROSE 10% IN PLASTIC CONTAINER
Dextrose 10% in Plastic Container: Market Dynamics, Patent Risk, and Financial Trajectory
Dextrose 10% injection in plastic containers is a mature, low-margin generic intravenous product. Its commercial value comes from recurring hospital demand, manufacturing reliability, contract access, and supply continuity rather than patent exclusivity. The product has no meaningful new-drug exclusivity, and its active ingredient is long off patent. Financial performance is therefore shaped by volume, procurement pricing, production costs, shortage conditions, and the number of qualified suppliers.
What is Dextrose 10% in Plastic Container?
Dextrose 10% injection is a sterile intravenous solution containing 10 grams of dextrose per 100 mL, equivalent to 100 mg/mL. It is used as a source of calories and water, for treatment or prevention of hypoglycemia, and in selected clinical situations requiring intravenous glucose administration.[1]
Common commercial presentations include:
| Product characteristic | Typical description |
|---|---|
| Active ingredient | Dextrose, USP |
| Strength | 10%, or 100 mg/mL |
| Route | Intravenous |
| Dosage form | Sterile solution for injection or infusion |
| Container | Flexible plastic bag or plastic container |
| Common volumes | 250 mL, 500 mL, and 1,000 mL, depending on manufacturer |
| Regulatory category | Prescription generic drug |
| Primary customers | Hospitals, outpatient facilities, emergency departments, and wholesalers |
| Commercial model | Institutional procurement, group purchasing, and distributor sales |
The plastic-container format is important because it reduces breakage risk compared with glass and supports automated hospital inventory systems. The container, port design, overwrap, stopper, and administration compatibility can differentiate otherwise interchangeable products.
How large is the Dextrose 10% injection market?
No major manufacturer generally reports revenue for Dextrose 10% in plastic containers as a standalone product. Public company filings typically group it with broader intravenous solutions, hospital products, or generic injectables. As a result, product-level revenue, market share, and profit data are not reliably disclosed.
The commercial market can be assessed through five demand drivers:
- Hospital admissions and emergency-care utilization.
- Neonatal, pediatric, and adult hypoglycemia treatment.
- Intensive-care and perioperative use.
- Pharmacy and nursing protocols requiring ready-to-use IV glucose.
- Government, hospital, and distributor inventory requirements.
Demand is relatively stable because dextrose injection is a protocol-driven hospital product. It is less exposed to consumer behavior than oral medicines. The market also has limited therapeutic substitution in situations where clinicians need a sterile, injectable glucose solution at a defined concentration.
The main constraint is pricing. Dextrose 10% is a standardized commodity product with multiple generic suppliers. Hospital systems and group purchasing organizations can negotiate aggressively, particularly when several manufacturers have available capacity.
What companies manufacture or distribute Dextrose 10% in plastic containers?
The U.S. injectable-dextrose market has historically included large hospital-product manufacturers and generic injectable companies such as Baxter, B. Braun Medical, Fresenius Kabi, and ICU Medical or its Hospira-related operations, depending on the specific National Drug Code and time period.[2][3]
The supplier set changes by presentation and market conditions. A company may manufacture the product, own the application, distribute another company’s product, or sell under a private-label arrangement. NDC-level verification is required before assigning a specific manufacturer to a particular container size.
Competitive structure
The market has the following characteristics:
| Competitive factor | Market effect |
|---|---|
| Mature active ingredient | Minimal product-level differentiation |
| Sterile manufacturing requirement | Limits entry compared with oral generics |
| Plastic-bag production | Requires specialized filling and packaging equipment |
| Hospital contracting | Favors established suppliers |
| Product interchangeability | Creates price pressure |
| Supply disruptions | Can rapidly increase the value of available inventory |
| Regulatory compliance | Makes manufacturing reliability a commercial asset |
| High shipment weight | Increases logistics and warehousing costs |
The most important competitive advantage is often not the lowest nominal price. It is the ability to maintain fill rates, meet hospital delivery windows, and support several container sizes without interruption.
When does Dextrose 10% lose exclusivity?
Dextrose 10% has no meaningful remaining market exclusivity in the United States. Dextrose has been used clinically for decades, and the product is sold through abbreviated or legacy generic pathways rather than through a current innovative-drug exclusivity model.
| Exclusivity category | Relevance to Dextrose 10% |
|---|---|
| New chemical entity exclusivity | Not applicable |
| Five-year New Drug Application exclusivity | Not applicable to this mature product |
| Three-year clinical-investigation exclusivity | Not generally applicable |
| Orphan-drug exclusivity | Not applicable |
| Pediatric exclusivity | No product-specific basis identified |
| Biosimilar exclusivity | Not applicable |
| Generic first-filer exclusivity | Product-specific and generally not a central commercial barrier |
| Patent exclusivity | No meaningful active-ingredient patent barrier |
The product’s economic protection comes from manufacturing qualifications, regulatory approvals, customer contracts, and supply-chain execution rather than intellectual property.
What patents protect Dextrose 10% in plastic containers?
No active-ingredient patent is expected to block generic manufacture of dextrose 10% injection. Dextrose is an established compound, and the commercial product is a conventional sterile aqueous solution.
Potential intellectual-property rights may relate to:
- Plastic container architecture.
- Port and connector systems.
- Container closure assemblies.
- Overwrap materials.
- Manufacturing equipment.
- Sterilization processes.
- Filling and sealing methods.
- Administration sets and compatibility systems.
These rights usually do not create a broad barrier to selling dextrose 10% injection. A competing manufacturer can often use a different container design, port configuration, or manufacturing process.
What is the Orange Book status of Dextrose 10%?
The Orange Book is relevant only to listed drug products and associated patent or exclusivity information. Dextrose 10% products may appear through specific approved applications, but an Orange Book entry for one product does not establish protection for every dextrose 10% plastic-container product.[4]
For commercial diligence, the decisive review is product-specific:
- Identify the reference or approved product.
- Confirm the application number.
- Review listed patents and exclusivity.
- Compare the dosage form, concentration, container, and route.
- Check whether any listed patent concerns the drug product, method of use, or device component.
The likely conclusion for a conventional dextrose 10% solution is that there is no broad, enforceable Orange Book estate comparable with branded small-molecule products.
Are Paragraph IV challenges relevant to Dextrose 10%?
Paragraph IV litigation risk is low relative to branded small-molecule drugs. Paragraph IV certifications arise when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. A conventional dextrose 10% product has limited patent subject matter capable of supporting a commercially meaningful challenge.
Potential disputes could arise if a patent covers:
- A proprietary flexible container.
- A specific closure or connector.
- A narrow formulation with excipients.
- A method of administration.
- A combination product involving a delivery device.
Such disputes would normally be product-specific. They would not necessarily prevent sale of dextrose 10% in a non-infringing container or through a different formulation.
What is the FDA regulatory status of Dextrose 10% injection?
Dextrose 10% injection is regulated as a sterile prescription injectable product. FDA approval depends on product quality, manufacturing controls, container-closure integrity, sterility assurance, labeling, and stability data.[1][5]
The principal regulatory risks are manufacturing risks rather than clinical-development risks:
- Sterility failures.
- Particulate contamination.
- Endotoxin excursions.
- Container leakage.
- Seal or port defects.
- Incorrect concentration.
- Labeling errors.
- Inadequate stability.
- Manufacturing-site inspection findings.
- Inability to maintain validated production capacity.
FDA enforcement action against a facility can have a greater immediate commercial effect than patent litigation. Injectable products are difficult to replace quickly because hospitals depend on approved, qualified suppliers and validated procurement channels.
What formulation patents protect Dextrose 10%?
The basic formulation is not highly differentiated. A typical product contains dextrose in water for injection, with pH and tonicity controlled through the manufacturing process and, where permitted, formulation design.
Commercially relevant formulation claims could concern:
- Osmolality control.
- pH ranges.
- Stability during terminal sterilization.
- Compatibility with plastic materials.
- Reduced degradation products.
- Specific preservative or electrolyte combinations.
- Premixed or ready-to-administer presentations.
For a plain Dextrose 10% Injection USP product, formulation patents are unlikely to create durable market exclusivity. The practical barrier is validating a sterile process and demonstrating product quality at commercial scale.
What manufacturing and intellectual-property barriers affect the market?
The strongest barriers are operational.
Sterile manufacturing capacity
Large-volume parenteral production requires validated filling lines, cleanrooms, sterilization systems, quality laboratories, and container-closure testing. Building or qualifying capacity can take years and require substantial capital investment.
Plastic-container technology
Plastic bags and containers must maintain sterility and physical integrity throughout manufacturing, shipping, storage, and use. The manufacturer must control extractables, leachables, oxygen and moisture transmission, port performance, and seal strength.
Regulatory approval
An approved generic product cannot be treated as interchangeable with an unapproved formulation. A new manufacturer must obtain FDA authorization, satisfy current good manufacturing practice requirements, and demonstrate compliance with applicable drug-product standards.
Distribution infrastructure
Dextrose solutions are heavy, bulky products. Freight, warehouse space, product rotation, and regional inventory placement can materially affect margins. Manufacturers with established hospital distribution networks have a cost advantage.
What drives the financial trajectory of Dextrose 10%?
The financial profile is typically low revenue per unit, high recurring volume, and limited gross-margin expansion. The main variables are listed below.
| Financial driver | Likely effect |
|---|---|
| Hospital procedure volume | Supports baseline demand |
| Supplier shortages | Can increase temporary pricing and volume for available suppliers |
| GPO contract awards | Can determine access to large accounts |
| Resin and packaging costs | Directly affect unit economics |
| Labor and energy costs | Increase sterile-production expenses |
| Freight costs | Material because of product weight |
| Manufacturing yield | Strong effect on profitability |
| Regulatory remediation | Can sharply reduce margins |
| Supplier concentration | Increases volatility during outages |
| Private-label sales | May increase volume but reduce price |
A supplier with high utilization and stable contracts can generate attractive returns despite low unit prices. A supplier operating below capacity can lose money because fixed costs are spread across fewer units.
Revenue exposure for diversified manufacturers
For diversified companies, dextrose 10% is usually a small component of total revenue. Its strategic value is greater than its standalone revenue contribution in three areas:
- Hospital account retention.
- Portfolio completeness within IV fluids.
- Capacity utilization for large-volume parenteral lines.
A manufacturer may keep a commodity product because it helps anchor a broader hospital supply contract that includes saline, lactated Ringer’s, amino acids, nutrition products, or administration systems.
How do shortages affect market pricing?
Shortages are the most important source of short-term market volatility. The product’s low-price baseline can change quickly when one or more suppliers experience a plant shutdown, quality event, raw-material constraint, or logistics disruption.
During a shortage:
- Hospitals may increase purchases from secondary suppliers.
- Distributors may ration inventory.
- Contract pricing may become less relevant than availability.
- Expedited freight and substitute presentations may raise costs.
- Manufacturers with available capacity can gain share.
- New entrants may face difficulty entering quickly because sterile approval and qualification take time.
The FDA Drug Shortages Database is the primary U.S. source for determining whether a particular dextrose presentation is in shortage and which manufacturers report supply constraints.[6] Shortage status can differ by concentration, container size, NDC, and manufacturer.
What generic launch scenarios exist for Dextrose 10%?
A new generic entrant would face limited patent risk but meaningful execution risk.
Scenario 1: Price-led entry
The entrant offers a lower-cost product to secure distributor or GPO contracts. This strategy can gain volume but may compress industry pricing and produce weak returns unless the manufacturer has efficient sterile capacity.
Scenario 2: Supply-security entry
The entrant markets redundant supply, domestic production, multiple container sizes, or stronger fill-rate commitments. Hospitals may pay a premium for reliability when shortages are frequent.
Scenario 3: Portfolio entry
The product is launched alongside other IV solutions. The manufacturer uses a larger product portfolio to win institutional contracts and improve manufacturing-line utilization.
Scenario 4: Shortage-driven entry
A supplier enters or expands during a market shortage. Revenue can rise sharply, but the opportunity may reverse when incumbent supply returns and contract prices normalize.
The most durable strategy is usually portfolio-based rather than dependent on sustained premium pricing for one dextrose concentration.
Which companies are challenging the market?
Competition is more likely to occur through commercial contracting and capacity expansion than through patent litigation. Large injectable suppliers, regional manufacturers, private-label distributors, and hospital purchasing organizations can all influence market access.
The principal competitive questions are:
- Which manufacturers have approved capacity?
- Which suppliers have current inventory?
- Which companies hold GPO contracts?
- Which container sizes are available?
- Which manufacturers can provide multiple IV-fluid products?
- Which suppliers have recent FDA compliance issues?
- Which companies can maintain supply during a disruption?
A company with a technically equivalent product but no distribution access may have limited commercial impact.
How does Dextrose 10% compare with other IV glucose products?
| Product | Typical commercial position | Key differentiation |
|---|---|---|
| Dextrose 5% | Broad routine hydration and calorie use | Lower glucose concentration |
| Dextrose 10% | Hypoglycemia and higher glucose delivery | Higher glucose concentration |
| Dextrose 25% or 50% | Concentrated emergency use | Greater osmolarity and administration constraints |
| Dextrose with electrolytes | Specialized fluid replacement | Combination formulation |
| Premixed nutrition products | Nutritional support | More complex formulation and clinical use |
Dextrose 10% occupies a middle position. It has broader handling requirements than dilute solutions but fewer formulation complexities than parenteral nutrition products.
What litigation and settlement agreements affect Dextrose 10%?
No major product-specific patent litigation or settlement framework is generally associated with conventional Dextrose 10% Injection in plastic containers. The absence of litigation is consistent with the product’s mature composition, generic status, and limited patent value.
Potential legal exposure is more likely to involve:
- Product liability.
- Manufacturing defects.
- Sterility claims.
- Contract disputes.
- FDA warning letters or recalls.
- GPO and distributor agreements.
- Container or administration-device patents.
A settlement involving one supplier’s container technology would not necessarily affect the market for all dextrose 10% products.
What is the geographic coverage of the market?
The United States is a major institutional market, but dextrose 10% injection is sold globally under different regulatory names, container formats, and reimbursement systems. Geographic performance depends on:
- National hospital procurement systems.
- Local sterile manufacturing capacity.
- Import controls.
- Pharmacopoeial standards.
- Cold-chain and warehouse infrastructure.
- Government tenders.
- Currency and freight costs.
U.S. market access requires FDA-compliant manufacturing and an approved product application. European, Canadian, and other markets require separate regulatory authorization and may use different tender structures.
How strong is the patent estate for Dextrose 10%?
The patent estate is weak as a source of exclusivity and moderate as an operational consideration.
| Patent category | Strategic strength |
|---|---|
| Dextrose active ingredient | Very weak |
| Basic aqueous formulation | Very weak |
| Standard IV indication | Very weak |
| Plastic container design | Potentially moderate but narrow |
| Port and connector design | Potentially moderate |
| Manufacturing process | Narrow and design-around risk |
| Device combination | Product-specific |
| Proprietary premix formulation | Stronger if clinically differentiated |
The commercial moat is therefore based on regulatory and manufacturing execution. A patent search should focus on container and administration technologies only when assessing a specific NDC or competitor product.
Key Takeaways
- Dextrose 10% in plastic containers is a mature generic IV product with no meaningful active-ingredient exclusivity.
- Product-level revenue and market share are generally not disclosed by manufacturers.
- Demand is stable and institutionally driven, but pricing is highly competitive.
- Sterile manufacturing capacity, container quality, FDA compliance, and distribution access are stronger barriers than patents.
- Paragraph IV and patent-litigation risk is low for a conventional formulation.
- Shortages can produce temporary pricing power and share gains for suppliers with available inventory.
- The most defensible commercial strategy is a broad IV-fluid portfolio supported by reliable supply.
- Financial performance depends on volume, capacity utilization, procurement contracts, packaging costs, logistics, and quality performance.
FAQs About Dextrose 10% in Plastic Containers
Is Dextrose 10% in plastic containers a branded or generic drug?
It is generally marketed as a generic sterile injectable product by hospital-product and generic-drug manufacturers.
Does Dextrose 10% have biosimilar competition?
No. Dextrose is a small chemical compound, not a biologic. Biosimilar regulation does not apply.
Can a hospital substitute one manufacturer’s Dextrose 10% product for another?
Substitution depends on the product’s approved labeling, institutional policy, pharmacy review, container specifications, and purchasing rules. Concentration and container volume must match the clinical requirement.
Are Dextrose 10% products listed in the FDA Orange Book?
Specific approved products may be represented in FDA databases, but Orange Book patent and exclusivity conclusions must be made at the application and NDC level.
What is the primary investment risk in the Dextrose 10% market?
The principal risk is operational disruption combined with low pricing power. A plant shutdown, quality problem, or loss of a hospital contract can reduce revenue quickly, while excess industry capacity can compress margins.
References
-
U.S. Food and Drug Administration. (2023). Dextrose injection prescribing information. FDA labeling database.
-
Baxter Healthcare Corporation. (2023). Dextrose injection, USP product information. Baxter product labeling.
-
Fresenius Kabi USA, LLC. (2023). Dextrose injection, USP product information. Fresenius Kabi product labeling.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2023). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. Electronic Code of Federal Regulations.
-
U.S. Food and Drug Administration. (2024). FDA Drug Shortages Database. FDA, Center for Drug Evaluation and Research.
More… ↓
